J&J drug shows promise in high-risk prostate cancer

Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease. ...

Hormone-depleting drug shows promise against localized high-risk prostate tumors

Researchers have demonstrated that a hormone-depleting drug approved for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a new clinical study.